Agennix   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Planegg United States (1997)
Status: Left NME R&D (2009)

Organization Overview

First Clinical Trial
2003
NCT00069745
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Agennix, Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

Key: Agennix (2) Acquired (1)

prednisone (meticorten) (1 trial)

satraplatin (12 trials)

talactoferrin alpha (6 trials)

Drugs in Phase 2 Trials (3)

erlotinib (tarceva) (1 trial)

lactoferrin (1 trial)

paclitaxel (taxol) (2 trials)

Drugs in Phase 1 Trials (4)

capecitabine (xeloda) (1 trial)

docetaxel (taxotere) (1 trial)

rgb286638 (1 trial)

vinorelbine (navelbine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 1)

Carcinoma, Verrucous (Phase 1)

Communicable Diseases (Phase 2)

Cross Infection (Phase 2)

Head and Neck Neoplasms (Phase 1)

Infections (Phase 2)

Laryngeal Diseases (Phase 1)

Laryngeal Neoplasms (Phase 1)

Lung Neoplasms (Phase 3)

Nasopharyngeal Carcinoma (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Unknown Primary (Phase 1)

Oropharyngeal Neoplasms (Phase 1)

Paranasal Sinus Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 1)

Salivary Gland Neoplasms (Phase 1)

Sepsis (Phase 3)

Tongue Neoplasms (Phase 1)

Toxemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 10